Skip to content

Study · Animal study (in vivo) · rat · 2020

1 result

Acute visceral pain relief mediated by A3AR agonists in rats: involvement of N-type voltage-gated calcium channels.

Lucarini E, Coppi E, Micheli L, Parisio C, Vona A, Cherchi F, Pugliese AM, Pedata F, Failli P, Palomino S, Wahl J, Largent-Milnes TM and 6 more

Show all authors

Vanderah TW, Tosh DK, Jacobson KA, Salvemini D, Ghelardini C, Di Cesare Mannelli L

Pain1 Sept 2020Cited by 23 (Europe PMC)

PMID32379223 (opens in a new tab)PMCIDPMC8272921 (opens in a new tab)DOI10.1097/j.pain.0000000000001905 (opens in a new tab)PepBankPUB-32379223
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with DNBS-induced visceral hypersensitivity, linaclotide produced pain relief comparable to A3AR agonists.

    In plain wordsIn rats, linaclotide relieved visceral pain similarly to A3AR agonists.

    Peptide
    Linaclotide
    Outcome
    No significant changeVisceral pain relief
    Study

    ratn: not reported in source

    DNBS-induced visceral hypersensitivity
    Comparator
    A3AR agonists MRS5980 and Cl-IB-MECA
    Outcome group
    Pain · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Efficacy was comparable to effects induced by linaclotide.
    2 context sentences
    Summary · context
    A3AR agonists significantly reduced DNBS-evoked visceral pain both in the postinflammatory (14 and 21 days after DNBS injection) and persistence (28 and 35 days after DNBS) phases.
    Summary · context
    The effects of A3AR agonists (MRS5980 and Cl-IB-MECA) were evaluated over time after DNBS injection and compared to that of the selective Cav2.2 blocker PD173212, and the clinically used drug linaclotide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.